Navigation Links
CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP

minimum of 28 days prior to enrollment. CRx-150 was dosed in this trial using 200mg of dipyridamole and two different doses of amoxapine (50mg titrating to 100mg after the first 2 weeks of treatment).

The Disease Activity Score using 28 joint counts (DAS28) is a composite score used to monitor disease activity in RA patients. The ACR20 score is a standard measure developed by the American College of Rheumatology to rate RA disease improvement. Patients are classified as ACR20 responders if they demonstrate a 20% improvement from baseline in tender and swollen joint count and at least 3 of 5 other symptom related criteria. C-reactive protein (CRP) is an acute phase protein and marker of systemic inflammation. A relationship between inflammatory processes and elevation of CRP has been established in a number of immuno-inflammatory diseases, including RA.

Conference Call Information

CombinatoRx management will host a conference call to discuss these results at 8:30 a.m. ET on Thursday, June 28, 2007. To access the call, please dial 800.591.6930 (domestic) or 617.614.4908 (international) five minutes prior to the start time and provide the pass code 97534941. A replay of the call will be available from 10:30 a.m. ET on June 28, 2007 until July 5, 2007. To access the replay, please dial 888-286-8010(domestic) or 617-801-6888 (international), and provide the passcode 26332727. A live audio webcast of the call will also be available on the "Investors" section of the company's website. An archived webcast will be available on the CombinatoRx website, www.combinatorx.com, approximately two hours after the event and will be archived for 14 days.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
2. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
3. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
4. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. PromegaExpress Expands Easy Access to Products with New Cabinet
11. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Post Your Comments:
(Date:11/27/2008)...lymphoblastic leukemia relapse cases arise from a ... , MEMPHIS, Tenn., Nov. 27 /PRNewswire-USNewsw... Hospital have identified distinctive genetic chan...phoblastic leukemia (ALL) that cause relapse. The ...or ALL relapse in children and, ultimately, in adu...
(Date:11/26/2008)..., FRANKLIN, Mass., Nov. 26 /PRNewswire-FirstCall...announced today that it has received full approval...for its U.S. pivotal trial to study the effectiven...sociated therapy in the prevention of Contrast-Ind...proved PLC,s request to expand their investigation...
(Date:11/25/2008)...t expanding statin use broadly in wake of AHA-pres... JUPITER, a clinical trial suggest... of healthy patients with elevated CRP, should not...rding to a national poll directed at health profes...online poll conducted by medical news site MedPage...
(Date:11/25/2008)...-FirstCall/ -- Pharmacyclics, Inc.,(Nasdaq: PCY... a Phase 1,clinical trial with PCI-27483, the com...r VIIa inhibitor. The trial was conducted in sixte... and pharmacologic effect of,PCI-27483. A single ...ose,response in the International Normalized Rati...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Martek to Announce Third Quarter 2007 Results on September 5 2007 83 1Martek to Announce Third Quarter 2007 Results on September 5 2007 83 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 1Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 4AUDIO from Medialink and GlaxoSmithKline 3A Fiber Key in Managing Irritable Bowel Syndrome 28IBS 29 Symptoms 77 1Ranexa 28R 29 Added to New ACC AHA Guidelines on Unstable Angina Non ST Elevation Myocardial Infarction 28UA NSTEMI 29 74 1Ranexa 28R 29 Added to New ACC AHA Guidelines on Unstable Angina Non ST Elevation Myocardial Infarction 28UA NSTEMI 29 74 2
...if., April 11, 2007,/PRNewswire-FirstCall/ -- Rige...update on R788, which is currently in ongoing,Phas...pura (ITP),rheumatoid arthritis (RA) and lymphoma...tor that blocks the activation of mast cells,macr...atory,responses and tissue damage. , Rigel commenc...
...SS WIRE)--Apr 11, 2007 - A comparison of,the long-...ug,therapies combined with symptom management vers...(R) (glatiramer acetate,injection) was the most co...tting multiple sclerosis (RRMS). The study provide...t-effectiveness of,multiple sclerosis (MS) therapi...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 2First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 3First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 5First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 6
(Date:12/2/2008)...ies, the problem with the holidays is family. Eld...ow caregivers of aging parents can bring the joy o... , San Mateo, CA (PRWEB) ...f the holiday season is family, especially aging p...er Koch , founder of Encore Management , has a si...
(Date:12/2/2008)...rofit Launches Age-related Macular Degeneration Ca...ible Patients and Free Eye-Healthy Cookbooks , ...cember 2, 2008 -- "Do You See What I See?&quo...n as Age-related Macular Degeneration (AMD) the an...his…. a large black hole in the center of y...
(Date:12/2/2008)...nnounces that the SouthEast Alaska Regional Health...ed the Rhapsody™ Integration Engine to help ... pharmacy, laboratory and business programs commun...nectivity to statewide systems such as VacTrAK (th...S (an MIS and clinical documentation tool used by ...
(Date:12/2/2008)... Provides Online Resource and Fire Safety Tips for... Boston, MA (PRWEB) December 2, 2008 -...eete , actress, philanthropist and mother of four,... a few moments before the holiday rush to review f...eSmart.com. , , , , ,Home fires top the list of A...
Breaking Medicine News(10 mins):Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 2Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 4
...A.P.J. Abdul Kalam Friday called for taking advant...ostic tool and of tele-radiology to help the needy...s speaking during a visit to the digital radiology...f India Limited (ECIL), which is working towards p...
...eshs Gorakhpur District are grappling to fight aga...is , that has killed at least 30 children in the p... Department, B.R.D Medical College, said that the ...ived over 100 patients since January out of whom 3...
...ay we interviewed a doctor - Dr.Makani Hemadri, wh...rrent problems facing the doctor community at lar...of healthcare systems in the world. Apparently alm...onal Health Service of England. In the US, Middle-...
Healthcare in India is presently the cynosure of global attention. A country that churns the highest number of medical brains, is also recording excellence in healthcare services. It is no longer wis
Other Medicine News:Health News:Interview With a Surgeon Hidden Hero of the NHS 2Health News:Interview With a Surgeon Hidden Hero of the NHS 3Health News:Interview With a Surgeon Hidden Hero of the NHS 4Health News:Interview With a Surgeon Hidden Hero of the NHS 5Health News:Interview With a Surgeon Hidden Hero of the NHS 6Health News:Interview With a Surgeon Hidden Hero of the NHS 7Health News:Interview With a Surgeon Hidden Hero of the NHS 8Health News:Lets Care For Our Physicians A Salute to Them on Doctors Day! 2Health News:Lets Care For Our Physicians A Salute to Them on Doctors Day! 3
...ing test for determining the presence of clinical ...randed system is considered the manual standard, a...r system meets defined NCCLS/ICSH guidelines desig...alized systems are also available for pediatric ap...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading.
...acids and is variably N-glycosylated. The variatio...tes of between 43 and 56 kDa. Insulin-like growth ... high affinity but do not bind insulin. Of the six...terized at this time, IGFBP-3 has been shown to be...
For the detection and semi-quantitation of antibodies against the Scl-70 antigen in serum as an aid in the diagnosis of autoimmune disease. The test can be performed either manually or in conjunction
Medicine Products: